Quantum Net Income from 2010 to 2026
| QNTM Stock | 3.95 0.01 0.25% |
Net Loss | First Reported 2016-03-31 | Previous Quarter -9.3 M | Current Value -5.3 M | Quarterly Volatility 4.8 M |
Check Quantum BioPharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Quantum BioPharma's main balance sheet or income statement drivers, such as Selling General Administrative of 13.3 M, Other Operating Expenses of 19.3 M or Total Operating Expenses of 19.1 M, as well as many indicators such as Price To Sales Ratio of 4.4 K, Dividend Yield of 0.0 or PTB Ratio of 0.34. Quantum financial statements analysis is a perfect complement when working with Quantum BioPharma Valuation or Volatility modules.
Quantum | Net Income | Build AI portfolio with Quantum Stock |
Evaluating Quantum BioPharma's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Quantum BioPharma's fundamental strength.
Latest Quantum BioPharma's Net Income Growth Pattern
Below is the plot of the Net Income of Quantum BioPharma over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Quantum BioPharma financial statement analysis. It represents the amount of money remaining after all of Quantum BioPharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Quantum BioPharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Quantum BioPharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (14.92 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Quantum Net Income Regression Statistics
| Arithmetic Mean | (12,225,519) | |
| Coefficient Of Variation | (111.17) | |
| Mean Deviation | 11,149,991 | |
| Median | (12,782,452) | |
| Standard Deviation | 13,590,983 | |
| Sample Variance | 184.7T | |
| Range | 39.1M | |
| R-Value | (0.61) | |
| Mean Square Error | 123.5T | |
| R-Squared | 0.37 | |
| Significance | 0.01 | |
| Slope | (1,643,738) | |
| Total Sum of Squares | 2955.4T |
Quantum Net Income History
Other Fundumenentals of Quantum BioPharma
Quantum BioPharma Net Income component correlations
About Quantum BioPharma Financial Statements
Quantum BioPharma investors utilize fundamental indicators, such as Net Income, to predict how Quantum Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -13.4 M | -14.1 M | |
| Net Loss | -17.2 M | -18 M | |
| Net Loss | (11.24) | (11.81) | |
| Net Income Per E B T | 1.10 | 1.12 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Quantum BioPharma Correlation against competitors. To learn how to invest in Quantum Stock, please use our How to Invest in Quantum BioPharma guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Will Biotechnology sector continue expanding? Could Quantum diversify its offerings? Factors like these will boost the valuation of Quantum BioPharma. Anticipated expansion of Quantum directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Quantum BioPharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Quantum BioPharma is measured differently than its book value, which is the value of Quantum that is recorded on the company's balance sheet. Investors also form their own opinion of Quantum BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Quantum BioPharma's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Quantum BioPharma's market value can be influenced by many factors that don't directly affect Quantum BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Quantum BioPharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Quantum BioPharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Quantum BioPharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.